recurr
infect
influenza
respiratori
virus
contribut
enorm
burden
human
diseas
emerg
sporad
zoonot
infect
influenza
middl
east
respiratori
syndrom
mer
coronaviru
pose
constant
threat
new
global
epidem
despit
extens
knowledg
virus
interact
host
littl
armouri
vaccin
therapeut
combat
perpetu
onslaught
isirv
antivir
group
confer
influenza
respiratori
viru
infect
advanc
clinic
manag
conven
tokyo
japan
june
attract
clinician
public
health
specialist
medic
scientist
countri
present
recent
research
discuss
variou
aspect
impact
respiratori
virus
differ
patient
groupsset
differ
region
world
focus
latest
advanc
mitig
clinic
manag
influenza
respiratori
viru
diseas
success
use
antivir
vaccin
season
pandem
influenza
particularli
japan
well
developmentassess
novel
antivir
agent
overview
highlight
main
point
emerg
present
oral
poster
associ
discuss
februari
china
detect
first
human
case
infect
sever
ill
patient
may
confirm
case
china
result
case
occur
mainli
two
wave
week
week
week
prior
exposur
poultri
contamin
live
poultri
market
median
time
poultri
exposur
diseas
onset
day
wherea
median
time
ill
onset
hospit
admiss
ard
develop
antivir
therapi
death
day
closur
live
poultri
market
markedli
reduc
risk
infect
across
nine
area
two
affect
provinc
china
model
analysi
estim
effect
market
closur
ci
retrospect
serolog
studi
blood
specimen
taken
subject
work
live
poultri
market
farm
slaughter
hous
kept
backyard
poultri
reveal
evid
indic
widespread
popul
suscept
lack
prior
circul
antigen
relat
virus
multipl
famili
cluster
report
sustain
humantohuman
transmiss
studi
demonstr
low
detect
viru
specif
antibodi
close
contact
first
second
wave
respect
healthcar
worker
posit
first
second
wave
major
patient
hospitalis
infect
older
men
median
age
year
respect
overal
malefemal
ratio
case
fatal
similar
respect
preexist
medic
condit
occur
case
promin
clinic
featur
admiss
sever
influenza
syndrom
fever
cough
fatigu
dyspnoea
strike
laboratori
find
mark
lymphopenia
thrombocytopenia
elev
cytokin
level
observ
patient
excess
cytokin
respons
may
contribut
clinic
sever
origin
reassort
event
involv
least
three
avian
influenza
virus
virus
multipl
genotyp
continu
emerg
frequent
basi
mani
virus
isol
human
contain
amino
acid
substitut
polymeras
compon
associ
mammalian
adapt
substitut
haemagglutinin
ha
associ
dual
receptor
bind
sialic
acid
virus
outbreak
date
antigen
similar
origin
candid
vaccin
strain
prototyp
inactiv
whole
particl
vaccin
investig
macaqu
shown
induc
good
antibodi
respons
significantli
reduc
number
day
viru
shed
experiment
infect
anim
treatment
patient
neuraminidas
inhibitor
nai
includ
intraven
iv
peramivir
appear
benefici
even
therapi
start
late
although
emerg
oseltamivir
resist
associ
poor
clinic
virus
amantadineresist
due
substitut
ion
channel
protein
virus
contain
substitut
neuraminidas
na
confer
resist
oseltamivir
peramivir
rise
reduc
suscept
zanamivir
laninamivir
rise
respect
report
six
case
two
patient
sever
infect
requir
extracorpor
membran
oxygen
ecmo
also
receiv
system
corticosteroid
treatment
lead
treatment
failur
poor
clinic
replic
transmiss
virus
contain
na
mutat
shown
compar
wildtyp
virus
guinea
ferret
follow
contact
noncontact
exposur
howev
wildtyp
viru
outgrow
strain
ferret
cours
interestingli
variant
appear
domin
viru
ferret
lung
lobe
nasal
turbin
wildtyp
viru
predomin
therefor
appear
mutat
caus
less
fit
loss
viru
season
new
reassort
genotyp
contain
ha
na
gene
clade
intern
gene
clade
emerg
associ
highest
number
case
n
death
n
global
sinc
confirm
case
death
report
infect
last
year
children
humantohuman
transmiss
remain
extrem
rare
base
virolog
serolog
data
analysi
close
contact
confirm
case
cambodia
thailand
studi
household
transmiss
pattern
indonesia
shown
overal
household
attack
rate
secondari
attack
rate
independ
household
oseltamivir
therapi
appear
reduc
mortal
administ
within
day
ill
onset
although
earlier
treatment
effect
highlight
need
earli
patient
earli
initi
oseltamivir
particularli
effect
reduc
mortal
patient
without
respiratori
failur
odd
ratio
p
wherea
requir
ventilatori
support
time
oseltamivir
initi
like
studi
risk
factor
mortal
relat
identifi
age
countri
per
capita
govern
health
expenditur
delay
symptom
onset
hospitalis
key
paramet
highlight
import
earli
diagnosi
treatment
support
highdos
system
corticosteroid
sc
associ
wors
outcom
one
human
case
avian
recent
detect
china
viru
reassort
contain
seven
gene
na
gene
viru
circul
china
also
report
detect
three
human
infect
two
fatal
avian
virus
contain
intern
gene
like
viru
viru
low
pathogen
poultri
therefor
difficult
detect
bird
pregnant
women
infant
increas
risk
complic
follow
influenza
infect
global
signific
number
pregnant
women
die
pandem
matern
mortal
occur
educ
campaign
direct
pregnant
women
healthcar
profession
pregnant
women
vaccin
result
infect
rate
among
pregnant
women
japan
compar
overal
infect
rate
popul
pregnant
women
infect
japan
treat
antivir
importantli
treat
within
day
symptom
mongolia
prospect
cohort
studi
found
influenzalik
ill
ili
detect
pregnant
women
major
test
posit
influenza
substanti
lower
influenza
b
respiratori
syncyti
viru
rsv
period
ili
detect
infant
month
age
even
spread
influenza
influenza
b
influenza
burden
children
rural
indian
commun
found
substanti
ili
case
caus
influenza
b
find
underscor
import
matern
sequenc
analysi
influenza
virus
isol
student
singapor
univers
campu
provid
insight
chain
transmiss
show
virus
highli
similar
demonstr
major
transmiss
occur
univers
campu
rather
infect
effect
surgic
mask
hand
hygien
health
educ
investig
household
hong
kong
bangkok
detect
signific
differ
attack
rate
cohort
use
one
analysi
data
enabl
insight
rel
import
aerosol
larg
droplet
contact
transmiss
within
household
influenza
infect
aerosol
transmiss
appear
common
rout
wherea
contact
transmiss
caus
highest
number
influenza
b
neuraminidas
inhibitor
commonli
use
treatment
influenza
japan
typic
follow
posit
result
pointofcar
poc
test
pandem
million
poc
test
kit
ship
hospit
clinic
japan
enabl
rapid
diagnosi
treat
case
administ
nai
within
hour
symptom
japan
oseltamivir
laninamivir
repres
nai
use
zanamivir
peramivir
use
consider
less
nai
effect
assess
numer
observ
studi
japan
oseltamivir
effect
significantli
reduc
patient
delay
treatment
durat
fever
viral
shed
longer
treat
patient
influenza
b
compar
influenza
viru
reduc
effect
influenza
b
virus
also
observ
trial
determin
whether
nai
reduc
mortal
pandem
data
compil
patient
hospitalis
confirm
compar
treatment
nai
treatment
associ
significantli
reduc
mortal
earli
treatment
also
show
reduc
risk
mortal
compar
late
treatment
although
signific
clinic
effect
compar
late
treatment
treatment
hospitalis
patient
signific
benefit
treat
patient
arriv
late
intens
care
household
prophylaxi
studi
inhal
laninamivir
given
either
day
reduc
ill
rate
within
household
respect
compar
household
given
ferret
model
oseltamivir
prophylaxi
shown
morbid
significantli
reduc
prophylaxi
regim
prevent
infect
significantli
reduc
viru
although
four
nai
sialic
acid
analogu
subtl
differ
chemic
structur
bind
properti
consequ
resist
pattern
vari
across
nai
commonli
detect
na
substitut
caus
nai
resist
influenza
virus
confer
resist
oseltamivir
peramivir
zanamivir
laninamivir
resist
mutat
becam
fix
season
virus
circul
late
cluster
virus
contain
substitut
detect
virus
commun
patient
receiv
nai
sapporo
reminisc
similar
cluster
oseltamivirresist
virus
commun
patient
australia
importantli
set
virus
contain
permiss
na
mutat
shown
ferret
studi
offset
destabilis
neg
effect
na
hospitalis
influenza
patient
treat
intraven
zanamivir
nextgener
sequenc
utilis
identifi
minor
resist
viru
popul
total
five
na
substitut
identifi
differ
virus
includ
howev
apart
present
low
proport
could
detect
sanger
popul
sequenc
effect
variou
mutat
catalyt
framework
residu
influenza
b
na
investig
use
revers
genet
rang
function
assay
four
substitut
confer
reduc
suscept
oseltamivir
three
substitut
caus
highli
reduc
inhibit
oseltamivir
zanamivir
two
variant
vitro
replic
fit
compar
naisuscept
virus
date
substitut
detect
rare
occas
circul
influenza
virus
intraven
formul
zanamivir
show
virolog
clinic
effect
without
safeti
concern
patient
hospitalis
influenza
rang
new
adamantan
deriv
good
antivir
activ
vitro
anim
model
virus
contain
ion
channel
substitut
confer
resist
favipiravir
novel
pyrazinamid
molecul
inhibit
replic
variou
rna
virus
includ
influenza
type
b
c
includ
oseltamivirresist
strain
recent
licens
japan
control
novel
reemerg
influenza
virus
triphosph
metabolit
rna
polymeras
inhibitor
disrupt
viru
genom
replic
synergi
oseltamivir
demonstr
preclin
phase
ii
studi
us
shown
twicedaili
regimen
decreas
titr
time
cessat
viru
shed
signific
benefit
reduc
clinic
symptom
http
wwwclinicaltrialsgov
subsequ
phase
iii
studi
current
ongo
neutralis
monoclon
antibodi
bind
ha
stalk
influenza
virus
group
group
ha
subtyp
effect
given
hour
postinfect
mice
ferret
infect
phase
iia
trial
human
show
antibodi
well
toler
mean
halflif
day
effect
therapi
high
dose
experiment
infect
volunt
upcom
placebocontrol
phase
iib
trial
target
hospitalis
influenza
patient
requir
oxygen
compar
combin
monoclon
antibodi
oseltamivir
oseltamivir
monotherapi
broadli
neutralis
antibodi
multipl
clade
gener
glycan
mask
key
ha
antigen
residu
direct
antibodi
respons
conserv
stem
region
flupep
novel
peptid
prevent
viru
entri
cell
shown
mous
studi
effect
reduc
viru
titr
lung
inflammatori
cytokin
fludas
hosttarget
therapeut
agent
remov
sialic
acid
cellular
receptor
respiratori
tract
thu
prevent
influenza
viru
bind
deliv
topic
effect
anim
model
lethal
infect
includ
nairesist
phase
rct
inhal
reduc
pharyng
viral
replic
uncompl
influenza
reduc
nasal
viru
load
improv
clinic
anoth
receptortarget
approach
develop
multival
sialic
acidbind
protein
singl
administr
day
preinfect
result
protect
mice
lethal
apart
block
sialic
acid
compound
appear
stimul
express
proinflammatori
mediat
therebi
prepar
immun
system
subsequ
influenza
infect
deliv
hour
postinfect
protect
howev
although
drug
resist
consid
less
like
occur
hostdirect
therapi
escap
mutant
develop
rapidli
follow
exposur
hostdirect
vacuolar
atpaseinhibit
furthermor
follow
serial
passag
differ
virus
presenc
bafilomycin
two
ha
mutat
select
result
reduc
drug
suscept
increas
virul
multipl
influenza
vaccin
effect
ive
studi
use
control
test
neg
design
approach
estim
ive
earli
late
phase
influenza
season
pandem
age
target
group
typic
ive
estim
rang
futur
studi
investig
ive
respect
type
influenza
vaccin
use
whether
ive
differ
start
end
season
effect
previou
vaccin
japan
ive
influenza
children
age
year
averag
ci
drop
ci
children
age
year
appar
influenza
b
age
group
ci
influenza
vaccin
effect
known
lower
adult
year
age
group
account
season
influenzarel
hospitalis
influenzarel
death
effort
improv
ive
elderli
recent
rct
investig
use
adjuv
intraderm
inject
higher
dose
antigen
use
influenza
vaccin
moder
superior
nonadjuv
vaccin
use
highdos
vaccin
contain
four
time
standard
level
ha
per
viru
result
improv
effect
compar
standard
dose
vaccin
manufactur
gener
highgrowth
reassort
certain
circul
virus
challeng
recent
studi
use
random
mutagenesi
select
highgrowth
clone
mdck
vero
cell
deriv
highgrowth
version
reassort
highgrowth
viru
hana
either
season
influenza
virus
show
yield
significantli
exceed
equival
reassort
contain
intern
gene
normal
juli
number
confirm
case
merscov
exceed
least
associ
major
case
involv
patient
comorbid
predomin
male
median
age
fewer
patient
report
contact
anim
includ
dromedari
camel
shown
one
like
anim
reservoir
base
seroposit
detect
infect
healthcar
worker
larg
number
nosocomi
infect
like
due
inadequ
infect
control
hospit
plu
enhanc
surveil
detect
substanti
number
mild
asymptomat
outsid
hospit
burden
diseas
like
larger
serolog
analysi
sever
uk
patient
found
rapid
rise
antibodi
day
titr
maintain
least
day
postinfect
anti
spike
glycoprotein
antibodi
respons
viru
neutralis
importantli
serolog
analys
patient
experi
mild
diseas
may
mount
modest
serolog
sequenti
sampl
three
case
involv
chain
transmiss
extens
analys
use
nextgener
variou
minor
variant
detect
transient
other
transmit
evid
variat
frequenc
variant
differ
bodi
compart
variou
therapeut
option
investig
treatment
merscov
therapi
proven
valu
current
exist
use
sc
associ
advers
outcom
recommend
merscov
mani
agent
shown
inhibitori
effect
merscov
cell
cultur
includ
interferon
ribavirin
cyclosporin
mycophenol
acid
chloroquin
interferon
lopinavir
mycophenol
possibl
alisporivir
combin
reason
choic
test
control
clinic
trial
exploratori
post
hoc
metaanalysi
studi
relat
sar
sever
influenza
shown
signific
reduct
mortal
follow
convalesc
plasma
treatment
compar
placebo
therapi
odd
ratio
ci
thu
earli
use
virusspecif
neutralis
antibodi
form
convalesc
plasma
monoclon
polyclon
neutralis
antibodi
treatment
merscov
highest
likelihood
clinic
modal
risk
like
exceed
benefit
includ
sc
ribavirin
monotherapi
respiratori
syncyti
viru
disproportion
impact
children
lowincom
almost
children
infect
rsv
birthday
number
one
caus
hospitalis
infant
us
caus
time
infant
death
addit
rsv
infect
adult
annual
account
commun
acquir
pneumonia
cap
burden
diseas
approach
caus
influenza
studi
conduct
hong
kong
hospitalis
adult
rsv
pneumonia
requir
supplementari
oxygen
mortal
rate
durat
hospit
stay
similar
observ
influenza
approxim
hospitalis
rsv
patient
bacteri
superinfect
although
corticosteroid
use
treat
patient
treatment
benefit
clinic
outcom
instead
increas
bacteri
secondari
infect
caus
longer
durat
rsv
replic
appear
prolong
patient
comorbid
lrt
complic
palivizumab
prophylaxi
prematur
infant
month
age
shown
reduc
hospitalis
due
rsv
prevent
rsv
infanc
associ
reduct
wheez
later
trial
monoclon
antibodi
typic
shown
achiev
superior
compar
palivizumab
therefor
achiev
licensur
furthermor
treatment
neutralis
monoclon
antibodi
appear
reduc
viru
load
diseas
sever
hospitalis
altern
option
rsv
therapi
assess
futur
clinic
trial
includ
inhal
nanobodi
aerosolis
peptid
nucleosid
analogu
rnainterfer
molecul
human
rhinovirus
hrv
usual
caus
mild
acut
respiratori
infect
occas
also
caus
sever
respiratori
infect
includ
exacerb
asthma
copd
japanes
children
asthma
respiratori
viru
detect
hrv
n
rsv
n
ex
vivo
bronchial
epitheli
cell
peopl
asthma
suscept
hrv
infect
due
defici
induct
ifnlambda
studi
asthmat
inhal
corticosteroid
therapi
histori
virusassoci
exacerb
patient
randomis
treatment
inhal
placebo
within
hour
develop
cold
symptom
patient
receiv
enhanc
morn
peak
expiratori
flow
recoveri
reduc
need
addit
treatment
boost
innat
immun
assess
blood
sputum
biomark
exploratori
analysi
subset
difficulttotreat
asthma
n
n
placebo
worsen
symptom
increas
significantli
placebo
group
prevent
p
picornavirusspecif
antivir
vapendavir
found
reduc
symptom
score
lower
bronchodil
puffer
use
reduc
viral
load
asthma
patient
urti
due
pointofcar
test
deliv
result
minut
avail
mani
countri
last
decad
good
specif
sensit
typic
poor
rang
compar
pcr
cultur
use
emerg
depart
hospit
result
reduc
unnecessari
antibiot
use
increas
likelihood
discharg
newer
immunofluorescencebas
poc
test
improv
sensit
develop
addit
quidel
sofia
poc
test
may
link
via
internet
result
report
realtim
central
databas
poc
test
use
photograph
silver
amplif
immunochromatographi
technolog
increas
pcr
remain
gold
standard
viru
diagnost
abil
rapid
sensit
specif
identifi
wide
rang
pathogen
via
differ
assay
abil
multiplex
multipl
pathogen
target
allow
cost
reduc
diagnost
set
new
closedsystem
technolog
involv
minim
handson
time
minut
conduct
autom
nucleic
acid
extract
pcr
multipl
pathogen
avail
current
limit
clinic
diagnost
purpos
due
lowthroughput
nextgener
sequenc
technolog
pcrbase
analys
increas
sensit
offer
consider
scope
diagnosi
although
current
understand
clinic
impact
pathogen
low
level
presenc
variant
minor
viru
popul
limit
provid
lowcost
sensit
assay
diagnos
respiratori
viru
infect
lowmiddleincom
countri
challeng
potenti
improv
treatment
avoid
unnecessari
antibiot
use
region
nitazoxanid
ntx
antiparasit
agent
approv
giardia
cryptosporidium
infect
also
inhibit
replic
vitro
influenza
respiratori
treatment
ntx
mg
twice
daili
day
associ
reduct
durat
symptom
particip
acut
uncompl
subset
analysi
patient
confirm
viru
infect
treatment
ntx
mg
also
led
shorter
time
allevi
symptom
comparison
placebo
versu
hour
p
review
prospect
observ
studi
shown
sc
increas
risk
mortal
morbid
eg
secondari
infect
hospitalacquir
pneumonia
sever
infect
due
influenza
especi
delay
antivir
sar
infect
higher
risk
avascular
necrosi
prolong
viru
shed
observ
patient
receiv
highdos
sc
therefor
import
avoid
use
highdos
sc
sever
respiratori
viral
infect
outsid
context
clinic
trial
larger
trial
need
resolv
uncertainti
regard
effect
earli
sc
therapi
ard
lowdos
sc
indic
manag
refractori
septic
short
cours
sc
indic
acut
exacerb
obstruct
airway
diseas
asthma
copd
current
evid
support
clinic
relev
effect
system
inhal
glucocorticoid
admiss
length
hospitalis
acut
viral
bronchiol
infant
young
immunocompromis
patient
influenza
exhibit
complic
longer
viru
shed
antivir
resist
often
demonstr
milder
clinic
symptom
sign
initi
clinic
influenza
virus
potenti
rapid
emerg
oseltamivir
resist
caus
sever
morbid
particularli
immunocompromis
patient
lymphopenia
delay
antivir
influenza
viraemia
may
serv
marker
overal
poor
outcom
increas
risk
progress
lrti
hypoxaemia
respiratori
failur
death
influenza
rna
blood
viraemia
detect
nine
hsct
recipi
influenza
among
patient
lrti
viraemia
associ
increas
hazard
overal
well
influenzaassoci
death
hazard
ratio
hsct
recipi
document
season
influenza
infect
treatment
highdos
corticosteroid
associ
trend
toward
prolong
viru
shed
ci
p
wherea
antivir
therapi
initi
treat
upper
respiratori
tract
infect
urti
associ
fewer
case
lrti
ci
p
fewer
hypoxaemia
episod
ci
p
view
risk
prolong
replic
drug
resist
longer
durat
higher
nai
dose
may
benefici
earli
therapi
consist
demonstr
improv
treatment
option
studi
use
tripl
combin
therapi
amantadin
oseltamivir
intraven
therapi
influenza
lung
transplant
recipi
associ
reduc
risk
develop
bronchiol
obliteran
inhibitori
piv
influenza
virus
includ
resist
amantadin
may
effect
treat
immunocompromis
patient
sever
piv
lung
studi
four
sever
immunocompromis
children
piv
diseas
treatment
day
dri
powder
inhal
nebulis
well
toler
transient
increas
serum
alkalin
phosphatas
liver
function
coagul
test
observ
nasal
wash
viru
load
reduc
patient
within
week
improv
clinic
rct
lung
transplant
recipi
rsv
infect
incid
new
progress
bronchiol
obliteran
syndrom
day
significantli
reduc
patient
receiv
small
interf
rna
rsv
ngene
compar
placebo
n
versu
p
larger
followup
multicentr
phase
iib
studi
treatment
show
greater
eightfold
reduc
risk
develop
bronchiol
obliteran
syndrom
day
adenoviru
seriou
often
fatal
infect
immunocompromis
patient
especi
hsct
recipi
control
adv
mostli
tcell
mediat
therefor
patient
receiv
tcell
suppress
regimen
increas
risk
adv
infect
annual
incid
adv
infect
hsct
recipi
rang
increas
like
due
increas
use
tcelldeplet
allograft
cord
blood
sourc
mortal
rate
brincidofovir
bcv
formerli
oral
bioavail
lipidconjug
cidofovir
cdv
provid
high
intracellular
concentr
cdv
diphosph
long
intracellular
halflif
day
bcv
potent
adv
cdv
vitro
low
risk
myeloid
nephrotox
gastrointestin
side
effect
retrospect
studi
immunocompromis
patient
given
bcv
adv
diseas
fail
intoler
iv
cidofovir
nine
patient
demonstr
virolog
respons
vr
defin
drop
baselin
undetect
adv
dna
serum
week
patient
vr
longer
surviv
without
vr
median
day
versu
day
p
